This is an early preclinical data release with no near-term catalyst date. The stock may see speculative movement, but the lack of a concrete clinical timeline or regulatory milestone limits actionable trading. Monitor for updates on IND filing or partnership announcements.
Price Chart
Executive Summary
Ernexa Therapeutics announced preclinical data showing its lead cell therapy candidate ERNA-101, combined with PD-1 blockade, achieved complete tumor clearance and 100% long-term survival in ovarian cancer models. The company plans to advance ERNA-101 toward a first-in-human clinical trial in advanced ovarian cancer. With a $5M market cap and no revenue, this is an early-stage, high-risk binary event with no near-term catalyst date.
Key Facts
- ERNA-101 in combination with anti-PD-1 therapy achieved complete tumor clearance and 100% survival in syngeneic ovarian cancer models.
- Data demonstrate tumor microenvironment remodeling from immunosuppressive to immune-activated.
- Company plans to incorporate findings into development strategy toward first-in-human clinical trial in advanced ovarian cancer.
- No specific timeline, financial data, or regulatory milestone dates provided.
- Market cap is $5M with no revenue; company is pre-commercial with no approved products.
Financial Impact
No financial figures disclosed; preclinical data only.
Risk Factors
- Preclinical results may not translate to human clinical trials.
- No timeline for first-in-human trial initiation.
- Company has no revenue and limited cash runway (not disclosed).
- Ovarian cancer is a competitive space with many failed therapies.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3288833 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | Press Release | $2.08 | awaiting T+5 | — | $1.94 (−6.51%) |
Oct 15, 2026 11d ago | 8-K | $2.09 $2.07 | ▼ −1.20% | ▼ −0.77% | $1.94 (−7.18%) |
Oct 1, 2026 25d ago | Press Release | $2.96 $2.49 | ▼ −15.88% | ▼ −17.18% | $1.94 (−34.46%) |
Sep 30, 2026 26d ago | Press Release | $3.20 $2.39 | ▼ −25.31% | ▼ −27.23% | $1.94 (−39.37%) |
Sep 16, 2026 5w ago | 8-K | $3.76 $3.62 | ▼ −3.72% | ▼ −4.32% | $1.94 (−48.40%) |
Sep 16, 2026 5w ago | 8-K | $3.76 $3.62 | ▼ −3.72% | ▼ −4.32% | $1.94 (−48.40%) |
Jul 14, 2026 14w ago | Press Release | $6.06 $5.43 | ▼ −10.40% | ▼ −9.10% | $1.94 (−67.99%) |
Jun 26, 2026 17w ago | 8-K | $7.03 $6.44 | ▼ −8.39% | ▼ −9.78% | $1.94 (−72.40%) |
Jun 17, 2026 18w ago | Press Release | $5.89 $6.30 | ▲ +6.96% | ▲ +8.00% | $1.94 (−67.06%) |
May 27, 2026 21w ago | Press Release | $11.14 $8.00 | ▼ −28.19% | ▼ −29.39% | $1.94 (−82.59%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers